Who are TBE booster vaccination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fIPV (0.2mL) IM, Havrix (HAV), Havrix Junior, IPV at 6 weeks of age, Hepatitis A (control), EV71 inactived vaccine（Vero cells）.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tbe-booster-vaccination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

TBE booster vaccination — Competitive Intelligence Brief

TBE booster vaccination (TBE booster vaccination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Tick-borne encephalitis virus envelope proteins Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

TBE booster vaccination (TBE booster vaccination) — Medical University of Vienna. TBE booster vaccination stimulates the immune system to produce antibodies and cellular immunity against tick-borne encephalitis virus through repeated antigen exposure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TBE booster vaccination TARGET	TBE booster vaccination	Medical University of Vienna	marketed	Inactivated viral vaccine	Tick-borne encephalitis virus envelope proteins
fIPV (0.2mL) IM	fIPV (0.2mL) IM	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine
Havrix (HAV)	Havrix (HAV)	Pfizer	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Havrix Junior	Havrix Junior	GlaxoSmithKline	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
IPV at 6 weeks of age	IPV at 6 weeks of age	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
Hepatitis A (control)	Hepatitis A (control)	International Vaccine Institute	marketed	inactivated viral vaccine	Hepatitis A virus surface antigens
EV71 inactived vaccine（Vero cells）	EV71 inactived vaccine（Vero cells）	Sinovac Biotech Co., Ltd	marketed	inactivated viral vaccine	Enterovirus 71 (EV71) viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TBE booster vaccination — Competitive Intelligence Brief. https://druglandscape.com/ci/tbe-booster-vaccination. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab